http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102327219-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9087e308705d4e0c80739b47a0e4107 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate | 2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b09a3d33b8784e7ecf8b8cedaa482030 |
| publicationDate | 2012-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102327219-A |
| titleOfInvention | Solid esomeprazole magnesium lipidosome preparation |
| abstract | The invention relates to a solid esomeprazole magnesium lipidosome preparation and a preparation method thereof. The solid esomeprazole magnesium lipidosome preparation is characterized by mainly comprising the following components according to weight part: 20 parts of esomeprazole magnesium, 50-100 parts of soybean lecithin, 50-150 parts of distearoyl phosphatidylglycerole, 50-150 parts of cholesterol and 150-200 parts of other general pharmaceutical excipients. According to the invention, the solid esomeprazole magnesium lipidosome preparation is prepared by adopting a reverse phase evaporation method, thus the bioavailability and the stability of the esomeprazole magnesium are greatly improved, toxic or side effects are greatly reduced, the quality of a preparation product and the curative effect is improved and the convenience for the clinical application is greatly realized. |
| priorityDate | 2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.